Skip to main content

BIOFIRE® Blood Culture Identification 2 (BCID2) Panel

1 Test. 43 Targets. ~1 Hour. 

The BIOFIRE BCID2 Panel tests for 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeast, and 10 antimicrobial resistance genes – all with one test and with results available in about an hour from positive blood culture.

  

Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country. 

 

Overview

The BIOFIRE® Blood Culture Identification 2 (BCID2) Panel tests a single positive blood culture sample to simultaneously provide results for multiple organisms and organism groups that cause bloodstream infections, as well as genetic markers associated with antimicrobial resistance. It is designed for use on the BIOFIRE® FILMARRAY® TORCH System, an FDA-cleared, CE-IVD, and TGA certified multiplex PCR system that integrates sample preparation, amplification, detection, and analysis.

  

Fast, Accurate, Comprehensive

Obtaining rapid blood culture organism identification, combined with the local antibiogram, allows for the timely adjustment of a broad-spectrum empiric antimicrobial therapy to a narrow, targeted patient treatment.1* The potential benefits of fast and comprehensive testing of bloodstream infections may include guided appropriate antibiotic therapy, decreased hospital length of stay2**, reduced hospital costs, and reduced patient morbidities and mortality

BIOFIRE BCID2 Panel can provide the essential combination of speed, accuracy, and comprehensiveness to enable a rapid, definitive identification of a pathogen directly from positive blood cultures. With just one test, you can identify pathogens in more than 9 out of 10 positive blood cultures in about 1 hour with only 2 minutes of hands-on time. 

  • Simple: 2 minutes hands-on time
  • Fast: Turnaround time of about 1 hour
  • Comprehensive: Simultaneously tests for 43 targets and identifies pathogens in more than 9 out of 10 positive blood cultures. The BIOFIRE BCID2 Panel detects 10 antimicrobial resistance genes and emerging pathogens like C. auris and S. maltophilia.
  • Accurate: The average positive agreement rate (or sensitivity) across all pathogens on the BIOFIRE BCID2 Panel is 99.0%, and the negative agreement rate (or specificity) is 99.8%3

  

Fighting Sepsis

Early identification and treatment of sepsis is essential to combat one of the leading causes of hospital patient deaths.4 The International Guidelines for the Management of Sepsis and Septic Shock recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens within 1 hour of recognition of the disease.5 However, it is estimated that early empiric antibiotic therapy is inappropriate in about 30% of patients.6 Moreover, it is a best practice according to the guidelines5 to narrow down antimicrobial therapy as soon as pathogens are identified, in order to reduce the occurrence of antimicrobial resistance.

  

Enhanced Antimicrobial Stewardship

The Infectious Diseases Society of America (IDSA) guidelines recommend the addition of rapid diagnostic testing to an effective Antimicrobial Stewardship Program.7 A study at the Mayo Clinic shows that pairing the Panel with antimicrobial stewardship provides the greatest benefit.*1

  

Adapted from Banerjee R, et al. Clinical Infectious Diseases 2015;61(7):1

  

Shorten Time to Optimal Therapy

                 

Combined with antimicrobial stewardship interventions, the time to optimal therapy decreased by 33.5 hours (obtained in a pediatric population and compared to SOC).8†

Reduce Hospital Costs

Faster organism identification and reduced time to optimal therapy can also lead to better economic outcomes. The identification of coagulase-negative staphylococci contaminants resulted in shorter post-culture length of stay and saved roughly $30,000 per 100 patients tested (obtained in a pre/post interventional study on an adult population).9‡

hospital and arrow

*Data obtained with the previous version of the BIOFIRE BCID2 Panel.

**Data obtained with the previous version of the BIOFIRE BCID2 Panel in a pediatric population.

Data obtained with the previous version of the BIOFIRE BCID2 Panel in a pediatric population and compared to Standard of Care (SOC).

Data obtained with the previous version of the BIOFIRE BCID2 Panel in a pre/post interventional study on an adult population.

  

References

1. Banerjee R, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015;61:1071-80.

2. Ray et al. Pediatr Infect Dis J 2016;35:e134-138

3. The stated performance is the aggregate of the prospective data from the clinical study.

4. Sepsis Alliance: Sepsis Fact Sheet 2018. https://www.sepsis.org/wp-content/uploads/2017/05/Sepsis-Fact-Sheet-2018.

5. Rhodes et al., Intensive Care Med. 2017 Mar;43(3):304-377

6. Zhang D, et al. Critical Care Medicine 2015;43(10):2133-2140

7. Barlam T, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Infectious Diseases Society of America. 2016;62(15 May). 

8. Messacar K, et al. Clinical Impact and Provider Acceptability of Real-Time Antimicrobial Stewardship Decision Support for Rapid Diagnostics in Children With Positive Blood Culture Results. J Ped Infect Dis Soc. 2017;6(3):267-274.

9. Pardo J, et al. Clinical and Economic Impact of Antimicrobial Stewardship Interventions with the FilmArray® Blood Culture Identification Panel. Diagn Microbiol Infect Dis. 2016;84(2):159–164.

Panel Menu

The BIOFIRE® Blood Culture Identification 2 (BCID2) Panel Menu

Gram-Negative Bacteria

  • Acinetobacter calcoaceticus-baumannii complex
  • Bacteroides fragilis
  • Enterobacterales
    • Enterobacter cloacae complex
    • Escherichia coli
    • Klebsiella aerogenes
    • Klebsiella oxytoca
    • Klebsiella pneumoniae group
    • Proteus spp.
    • Salmonella spp.
    • Serratia marcescens
  • Haemophilus influenzae
  • Neisseria meningitidis
  • Pseudomonas aeruginosa
  • Stenotrophomonas maltophilia

Gram-Positive Bacteria

  • Enterococcus faecalis
  • Enterococcus faecium
  • Listeria monocytogenes
  • Staphylococcus spp.
    • Staphylococcus aureus
    • Staphylococcus epidermidis
    • Staphylococcus lugdunensis
  • Streptococcus spp.
    • Streptococcus agalactiae
    • Streptococcus pneumoniae
    • Streptococcus pyogenes

Antimicrobial Resistance Genes

  • Carbapenemases
    • IMP
    • KPC
    • OXA-48-like
    • NDM
    • VIM
  • Colistin Resistance
    • mcr-1
  • ESBL
    • CTX-M
  • Methicillin Resistance
    • mecA/C 
    • mecA/C and MREJ (MRSA)
  • Vancomycin Resistance
    • vanA/B

Yeast

  • Candida albicans
  • Candida auris
  • Candida glabrata
  • Candida krusei
  • Candida parapsilosis
  • Candida tropicalis
  • Cryptococcus (C. neoformans/C. gattii)

FDA Cleared

Services & Support

Customer Support: bioMérieux offers the best possible support with dedicated BIOFIRE® technical experts.

Application Specialists: bioMérieux has dedicated support teams who are available to help set up equipment and troubleshoot any issues.

For assistance: please contact our customer technical support team at biofiresupport@biomerieux.com

Specs & Resources

Technical Panel Specifications

Sample HandlingPerformance Parameters
Sample Type: Positive Blood Culture MediaHands-on Time: Approx. 2 minutes
Sample Volume: 0.2 mLRun Time: ~ 1 Hour

 

Product NamePart NumberQuantity
BIOFIRE®  BCID2 Panel Reagent KitRFIT-ASY-014730 Pouches

Resources